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Cryptococcosis, an invasive mycosis caused by Cryptococcus spp, kills between 20%
and 70% of the patients who develop it. There are no vaccines for prevention, and
treatment is based on a limited number of antifungals. Studying fungal virulence and how
the host responds to infection could lead to new therapies, improving outcomes for
patients. The biggest challenge, however, is that experimental cryptococcosis models do
not completely recapitulate human disease, while human experiments are limited due to
ethical reasons. To overcome this challenge, one of the approaches used by researchers
and clinicians is to: 1) collect cryptococcal clinical isolates and associated patient data; 2)
study the set of isolates in the laboratory (virulence and host-pathogen interaction
variables, molecular markers); 3) correlate the laboratory and patient data to
understand the roles fungal attributes play in the human disease. Here we review
studies that have shed light on the cryptococcosis pathophysiology using these
approaches, with a special focus on human disease. Isolates that more effectively
evade macrophage responses, that secrete more laccase, melanize faster and have
larger capsules in the cerebrospinal fluid are associated with poorer patient outcomes.
Additionally, molecular studies have also shown that cryptococcal clades vary in virulence,
with clinical impact. Limitations of those studies include the use of a small number of
isolates or retrospectively collected clinical data. The fact that they resulted in very
important information is a reflection of the impact this strategy has in understanding
cryptococcosis and calls for international collaboration that could boost our knowledge.
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INTRODUCTION
The genus Cryptococcus is one of the deadliest among those that cause systemic mycoses in humans
(Bongomin et al., 2017). Pathogenic species are part of the C. neoformans and C. gattii complexes,
but the genus includes many other species that are rarely or never pathogenic to humans and
animals (Enoch et al., 2017; Kwon-Chung et al., 2017). These encapsulated yeasts are normallygy | www.frontiersin.org April 2021 | Volume 11 | Article 6575021
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have evolved complex virulence factors that allow them to
survive and multiply in the human host is an important
question that has been the target of research for decades.
Beyond being interesting from an evolutionary point of view,
cryptococcal virulence and its interaction with the human host
are also clinically critical.
A global epidemiology study estimated that each year the
disease kills 181,100 out of 223,100 individuals it affects
(Rajasingham et al., 2017). Mortality rate estimates in this
study were of up to 70% in low-income countries; however,
even in optimal settings in high-income countries in North
America and Europe, the estimated mortality rates range
around 20% - 30%. One of the reasons for that is the limited
arsenal of antifungals to treat the disease, with basically just
three drugs: amphotericin B, flucytosine and fluconazole.
Amphotericin B can be cheap (US$ 3.80 per dose) but very
toxic in its deoxycholate formulation (Bicanic et al., 2005),
whereas lipidic formulations are safer (Faustino and Pinheiro,
2020) but very expensive (US$ 443 per dose for the liposomal
and US$ 506 per dose for the lipid complex formulations, all
prices in Brazil for the year 2016) (Borba et al., 2018). Flucytosine
improves the efficacy of amphotericin therapy, but is toxic and
not available in most countries, whereas fluconazole is ineffective
as monotherapy (Lu et al., 2019). As exemplified by tetanus,
diphtheria and several other infectious diseases, virulence factors
are frequent therapeutic and prophylactic targets. Studying the
host response is also very important, because it could lead to
host-directed therapies that would be very important in a disease
in which immunocompromise is the major risk factor. Thus,
research on virulence and host-pathogen interaction has great
potential in decreasing the disease burden of cryptococcosis.
An important problem, however, is that it is very difficult to
study virulence and host-pathogen interaction in human beings.
A key experiment in determining a microbe’s virulence attributes
is to impair functionality of the genes that encode them and
compare the outcomes of experimental infection with the
original strain and the mutants. On the host side, a frequent
approach to test hypotheses involves infecting genetically
modified animals and comparing the outcome with wild-type
animals. However, neither approach is feasible in humans.
Experiments like these have been done extensively in animal
models, but they do not always recapitulate human diseases. For
example, mice succumb to cryptococcal infection (Goldman
et al., 1996; Carroll et al., 2007) and commonly used
immortalized macrophages have weak in vitro fungicidal
activity (Pan et al., 2009). In contrast, an intact immune
response in healthy human beings effectively deals with the
fungus in most individuals as evidenced by the fact that most
people are infected with Cryptococcus spp. during their early life
(Goldman et al., 2001) but the incidence of cryptococcosis in the
HIV uninfected is a few cases per million people per year (Chen
et al., 2000; Mirza et al., 2003).
One strategy that researchers have used to obtain information
about virulence and host-pathogen interaction in humans starts
with collecting clinical isolates together with information fromFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 2the patients from whom each isolate was obtained. The
microorganisms are then studied in the laboratory, where
virulence attributes and host-pathogen interaction variables are
systematically measured. The laboratory measurements are then
correlated with patient data, revealing how virulence attributes
are associated with the outcome of the disease (Figure 1).
Additionally, many groups have used biochemical, serological
or more recently molecular tools such as multi-locus sequence
typing (MLST) or genome sequencing to phylogenetically
classify clinical isolate collections, and then correlated this
information with patient data as well. This approach has been
used extensively to study other pathogens, resulting for example
in important insight on the virulence of Candida albicans
(Rajendran et al., 2016), Mycobacterium tuberculosis (Lan et al.,
2003) and Plasmodium falciparum (Bernabeu et al., 2016). In this
paper, we review some of the knowledge we have acquired on
human cryptococcosis using these strategies and discuss both
existing limitations and what could be done to further progress
in this area.
Virulence and Host-Pathogen Interaction
in Humans
The pathogenesis of pulmonary cryptococcosis or cryptococcal
meningitis depends on the host immune status and is influenced
by several fungal virulence factors (Bicanic and Harrison, 2004).
The most studied Cryptococcus virulence factors are the
polysaccharide capsule (Ngamskulrungroj et al., 2011;
Robertson et al., 2014), the ability to produce melanin
(Ngamskulrungroj et al., 2011; Renney de Sousa et al., 2020),
thermotolerance (Johnston et al., 2016) and the production
enzymes such as laccase (Frazão et al., 2020), urease (Shi et al.,
2010) and phospholipases (Santangelo et al., 2004).
The capsule was the focus of a study made by Robertson and
colleagues with Cryptococcus spp. isolates from HIV-infected
Ugandan adults as part of a clinical trial (Robertson et al.,
2014). They measured the capsule thickness and capsular
polysaccharide shedding both ex vivo, in the patients’
cerebrospinal fluid (CSF), and in vitro, after culture in the
laboratory. There was no correlation between the two sets of
measurements, an indication that the complex environment
inside the human host is not fully reproduced in the laboratory.
Interestingly, the authors found that isolates with larger ex vivo
capsules were found in patients with higher CSF cryptococcal
antigen titers, less intense central nervous system (CNS)
inflammation and higher intracranial pressure. Beyond the
capsule, other morphologic aspects of the Cryptococcus spp.
cell affect patient outcomes (Fernandes et al., 2018). C.
neoformans and C. tetragattii isolates from Botswana were
cultivated in vitro and observed microscopically, with multiple
morphologies such as giant cells, micro cells and shed capsule
fragments. Higher pleomorphism, with a more diverse mix of
cell shapes and sizes, was associated with increased risk
of death.
The important role of the CNS environment for disease
outcome was also highlighted by a second study from the same
group (Sabiiti et al., 2014). This study, performed with clinicalApril 2021 | Volume 11 | Article 657502
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South Africa, focused on the fungal interaction with
macrophages and on melanin and the enzyme that
synthesizes this pigment, laccase. The authors found that
some isolates were more efficiently phagocytosed by
macrophages than others, and that those with higher in vitro
uptake by macrophages were isolated from patients with higher
CSF fungal burden and higher risk of death. The high-uptake
strains were also hypocapsular and had higher laccase activity
than the low-uptake strains. Surprisingly, uptake by
macrophages correlated positively with laccase activity but
not with total melanin produced by each isolate. This
observation hinted at melanin-independent activities for
laccase, a hypothesis that was proven by in vitro exposure of
the clinical isolates to CSF. The fluid was toxic to fungi,Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 3but strains with increased laccase activity were able to
survive better.
Melanin-independent roles for laccase were also central in
two recent studies we conducted with Brazilian Cryptococcus spp.
Isolates. In one of them, we measured the non-lytic exocytosis of
a small set of C. neoformans isolates (Frazão et al., 2020). This is a
process in which macrophages expel Cryptococcus spp. cells
without harm to either cell (Alvarez and Casadevall, 2006; Ma
et al., 2006), and its mechanism is not fully understood. We
found that isolates that melanized faster were expelled more
frequently. Further experiments showed that what affected the
non-lytic exocytosis was actually laccase, not melanin, because
pre-melanizing cells did not alter the rates but knocking out
laccase did. In another study, at the moment of writing still at the
preprint stage (Renney de Sousa et al., 2020), we measuredFIGURE 1 | Experimental strategy of translational studies in cryptococcosis. Individual research groups collect patient data and clinical isolates. Information about
the isolates is then collected experimentally in the laboratory and finally correlated with clinical data. Figure generated using Biorender.com.April 2021 | Volume 11 | Article 657502
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deuterogattii isolates, especially the capsule and laccase/
melanin. As previously reported (Robertson et al., 2014;
Fernandes et al., 2018), we did not observe any correlations
between in vitro capsule phenotypes and clinical outcomes; we
also observed that secreted laccase activity negatively correlates
with survival in both cryptococcosis patients and Galleria
mellonella animal models, in line with previous observations as
well (Sabiiti et al., 2014). However, we did observe an important
role for melanization rate in survival of both G. mellonella and
humans, irrespective of laccase secretion. The risk of death was
positively associated with how fast each isolate melanized.
The interaction between C. neoformans and murine
macrophages was the focus of a study made with clinical
isolates obtained in a French prospective study (Alanio et al.,
2011). Alanio and collaborators observed great variation in the
phagocytosis and intracellular proliferation of fungi inside
infected macrophages. Isolates that more effectively evaded
phagocytosis (low phagocytic index) and had lower
intracellular proliferation rates were associated with a higher
risk of therapeutic failure, determined as lack of CSF sterilization
at 2 weeks. Isolates that were more efficiently phagocytosed but
proliferated more efficiently inside macrophages were obtained
from patients with a higher risk of death. These findings
confirmed that the Cryptococcus-macrophage interaction,
which in studies with mice and other animal models is crucial
for disease outcome, is also important in infected humans.
Another study with clinical isolates also found clinical
outcomes that parallel those of mouse models (Mukaremera
et al., 2019). Using an inhalation infection model, the authors
show a strong association between the mortality rates in humans
and mice. They have also found that survival in both hosts is
dependent on the burden of fungal cells in affected tissues and on
each isolate’s growth speed and resistance to stresses.
Genotypic Diversity
For many years, C. neoformans was considered a unique species
with four serotypes based on differences in capsule antigenicity.
Further characterization of those serotypes revealed
epidemiological, biochemical, and genetic differences among them
that lead to their subdivision into four varieties: C. neoformans var.
grubii (serotype A), C. neoformans var. gattii (serotypes B and C)
and C. neoformans var. neoformans (serotype D). Genetics and
molecular biology advances during the last two decades resulted in
more precise phylogenetic characterization of the different varieties
leading first to their separation into two species with different
molecular types (C. neoformans VNI, VNII, VNB, VNIII and
VNIV and C. gattii VGI, VGII, VGIII and VGIV) and later in
seven different species (Kwon-Chung and Varma, 2006; Lin and
Heitman, 2006; Hagen et al., 2015). Species in the C. neoformans
complex are usual ly opportunist ic , causing mostly
meningoencephalitis in immunocompromised individuals. In
contrast, those in the C. gattii complex are more frequently
primary pathogens and are associated with pneumonia in
addition to meningoencephalitis (Galanis and MacDougall, 2010).Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 4Most genetic studies with clinical isolates focus on the
geographic distribution of the different molecular types, with
only a few presenting correlations with clinical data. Most of
these are focused on the C. neoformans complex, especially the
most common VNI (C. neoformans strictu sensu) molecular type,
the most frequent cause of cryptococcosis worldwide. Wiesner
and collaborators found a significant association between the
genotype and phenotype of clinical strains of C. neoformans VNI
and severity of cryptococcal meningitis (Wiesner et al., 2012).
Multilocus sequencing typing (MLST) of their isolates resulted in
four clonal clusters and three nonredundant evolutionary groups
which presented significant differences in patient mortality. The
isolates obtained from patients with higher mortality also
presented increased capsular polysaccharide shedding and
induced a more pronounced Th2 response ex vivo. Similarly,
other studies have shown that specific subgroups within the
C. neoformans VNI clade are associated with more or less
severe disease:
• A specific sequence type named ST5 is associated with the
development of lymphadenopathy and higher blood
lymphocyte counts in patients, as well as with worse
disability outcomes in people who were cured (Day et al.,
2017).
• Among HIV-positive patients from five countries in Asia and
Africa, three VNI subclades were found. Individuals infected
with isolates from the VNIa-93 subclade, commonly reported
in Uganda and Malawi, had lower mortality than those
infected with the VNIa-4 and VNIa-5 subclades (Ashton
et al., 2019).
As for other clades within the C. neoformans complex, two
other studies have correlated molecular and clinical data. Using
isolates from HIV-positive patients in South Africa, Beale and
colleagues found that the VNB lineage was linked to worse
patient survival (Beale et al., 2015). They also found an
association between the fungal genotype and virulence
phenotypes in isolates from the VNII lineage, which had
increased laccase activity and ex vivo survival on CSF, fungal
phenotypes that were previously associated with poorer disease
outcomes (Sabiiti et al., 2014). The second report was from the
French Cryptococcosis Study Group, who characterized
C. neoformans isolates from the hybrid AD serotype (Desnos-
Ollivier et al., 2015). Their data showed that patients infected
with AD hybrids had lower fungal dissemination, less frequent
lung involvement and more frequent CSF sterilization after
treatment compared to patients infected with either serotype A
or D.
Most of what has been learned about human cryptococcosis
with this strategy of correlating molecular and patient data has
been done with multi-locus sequence typing. The most recent
studies, however, have begun to use whole genome
sequencing, which is far more robust and results in richer,
more detailed data. Gerstein and collaborators have used
whole genome sequence typing to characterize a set of
clinical isolates (Gerstein et al., 2019). Their work, however,April 2021 | Volume 11 | Article 657502
de Sousa et al. Cryptococcal Virulence in HumansFIGURE 2 | Proposed strategy of translational studies in cryptococcosis as an international collaboration. Cryptococcus spp. clinical isolates from all over the world
would be gathered in a single biobank; all associated clinical data would equally be gathered in a single open database. Each laboratory would receive all isolates
available in the biobank and would be responsible for measuring one or a few virulence factors according to its expertise. All data would finally be combined and
analyzed together, increasing statistical power. Figure generated using Biorender.com.Frontiers in Cellular and Infection Microbiology | www.frontiersin.org April 2021 | Volume 11 | Article 6575025
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information we get from this type of study: genome-wide
association studies. The authors identified hundreds of
polymorphisms in the genome sequences and correlated
those with clinical data, as well as with laboratory
information on virulence and host-pathogen interaction.
This strategy resulted in 40 C. neoformans genes associated
with human disease, many of them with unknown functions.
Knockout strains were available for 17 of these, and mouse
models proved that 35% were indeed less virulent than the
wild-type C. neoformans. We believe this powerful new
approach will result in very important information in the
next few years.THE WAY FORWARD – MULTINATIONAL
COLLABORATION
The selected studies we reviewed above have brought important
insights on Cryptococcus spp. virulence and the host response in
cryptococcosis. They have, however, important limitations. One
of these limitations is intrinsic to the experimental strategy itself:
correlation does not imply causation. Experiments like these are
thus often followed up with additional experiments to confirm
hypotheses raised by the correlations with clinical data. Other
important limitations are:
• Most of the papers we reviewed were made with dozens or a
few hundred isolates that originated from a single geographic
region. The small number of isolates tested means that the
studies are powered to discover only strong correlations,
whereas the similar origin from all isolates reduces the
breadth of the diverse genetic landscape being probed.
• Most often different studies are made with different sets of
clinical isolates that were collected by different researchers,
hindering reproducibility. It is difficult to distribute and share
pathogenic isolates and clinical data with other researchers
who could count on existing datasets.
• Microbiology techniques and molecular characterization
methodologies vary between research groups, as do
strategies used to diagnose and treat the disease. The quality
of the clinical data collected also varies a lot, with a tendency
for more uniform and complete data when the strains
originate from clinical trials in comparison with less precise
information gathered retrospectively from patient charts in
observational studies.
• The same virulence attributes are measured differently by
each research group. For example, Robertson et al. measured
the cryptococcal capsule sizes from clinical isolates directly
out of the CSF (Robertson et al., 2014), whereas we (Frazão
et al., 2020; Renney de Sousa et al., 2020) and others
(Fernandes et al., 2018) have measured it in isolates grown
in vitro in different media.
• Different groups correlate virulence and host-pathogen
interaction information with different aspects of the patientFrontiers in Cellular and Infection Microbiology | www.frontiersin.org 6outcome. Alanio et al. for example, made correlations with
therapeutic efficacy, measured by CSF sterilization after two
weeks, and death after three months of diagnosis (Alanio et al.,
2011). On the other hand, Robertson et al. (2014) correlated
their data with intracranial pressure, fungal clearing and CSF
inflammation whereas Sabiiti et al. (Sabiiti et al., 2014) used
CSF fungal burden and 10-week survival.
The fact that very important information regarding the
pathogenesis of cryptococcosis has been obtained from these
studies despite the many limitations means that much more can
be understood about the disease with this strategy. Overcoming
these limitations, however, would probably require a different
approach than what has already been used. Problems with low
statistical power and genetic variety can be solved by creating
collections with hundreds to thousands of isolates from different
regions of the planet (Figure 2). Ideally, these isolates would be
molecularly characterized with the gold standard (full genome
sequencing) and both fungi and associated clinical, molecular,
virulence and host-pathogen data would be deposited in publicly
available repositories, to allow other researchers to build upon
existing knowledge.
This would probably only be possible through worldwide
collaborative work between clinicians and basic scientists
working on Genomics, Microbiology and Immunology. Such
collaboration could also decrease the heterogeneity of patient
variables to be collected and the choice of laboratory techniques
and data analysis strategies, which could be agreed upon
prospectively. This is a complex and laborious proposition, but
one that could result in advances that lead to improved outcomes
for people dying from cryptococcosis.AUTHOR CONTRIBUTIONS
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